vimarsana.com

Latest Breaking News On - Eledon pharmaceutical - Page 2 : vimarsana.com

Is Eledon Pharmaceuticals (NASDAQ:ELDN) In A Good Position To Deliver On Growth Plans?

We can readily understand why investors are attracted to unprofitable companies. For example, although.

HC Wainwright Weighs in on Eledon Pharmaceuticals, Inc s Q2 2023 Earnings (NASDAQ:ELDN)

Eledon Pharmaceuticals, Inc. (NASDAQ:ELDN – Get Rating) – HC Wainwright issued their Q2 2023 EPS estimates for Eledon Pharmaceuticals in a research report issued to clients and investors on Friday, May 26th. HC Wainwright analyst V. Bernardino anticipates that the company will earn ($0.47) per share for the quarter. The consensus estimate for Eledon Pharmaceuticals’ […]

Cantor Fitzgerald Reaffirms Overweight Rating for Eledon Pharmaceuticals (NASDAQ:ELDN)

Cantor Fitzgerald reissued their overweight rating on shares of Eledon Pharmaceuticals (NASDAQ:ELDN – Get Rating) in a report published on Monday morning, PriceTargets.com reports. Cantor Fitzgerald also issued estimates for Eledon Pharmaceuticals’ FY2023 earnings at ($1.83) EPS. Eledon Pharmaceuticals Stock Down 0.4 % Shares of NASDAQ:ELDN opened at $2.24 on Monday. The stock has a […]

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.